| Name | Title | Contact Details |
|---|---|---|
Jaya Gautam |
Senior Vice President of Technical Operations | Profile |
BioDuro-Sundia provide its biopharma customers a single end-to-end solution from early stage drug discovery to late stage manufacturing.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare.
We partner with exceptional scientists to bring a new class of medicines to patients in need, built around understanding the deep science of the “Nine Hallmarks of Aging” with the potential to both treat and prevent today`s deadliest diseases.
Marina Biotech is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.